Stanton R. Mehr - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Stanton R. Mehr's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Stanton R. Mehr
Verified
Principal, Biosimilars Review & Report
Philadelphia
Beats
Space , Animals, Health , Biology, Environment, Science
Content
Biosimilar Bytes: Eculizumab Biosimilar Launches, Rights to Actemra Biosimilar Sold, and New Biosimilar Bevacizumab Approved
By Stanton R. Mehr| Biosimilars Review & Report@ It’s been a busy couple of weeks, and we’re taking this time to catch up on some specific biosimilar product news. The biosimilar maker Samsung Bioepis and its marketing partner Teva Pharmaceuticals announced on April 7 that it had launched Epysqli in the United States. This is the second eculizumab biosimilar to be commercialized. Epysqli will be available at a 30% discount to the list price (or wholesale acquisition cost) of the reference product Soliris.
By Stanton R. Mehr| Biosimilars Review & Report@ On Tuesday April 8th the House Subcommittee on Health (of the Ways and Means Committee) held a hearing on lowering costs for patients and the health of the biosimilar market. The testimony of several experts in the biologics and biosimilar areas supported the need to recalibrate PBMs’ relationship to the biosimilar market as well as readjust federal policy on biosimilar reimbursement and development.
Biosimilar Bytes: Eculizumab Biosimilar Launches, Rights to Actemra Biosimilar Sold, and New Biosimilar Bevacizumab Approved
By Stanton R. Mehr| Biosimilars Review & Report@ It’s been a busy couple of weeks, and we’re taking this time to catch up on some specific biosimilar product news. The biosimilar maker Samsung Bioepis and its marketing partner Teva Pharmaceuticals announced on April 7 that it had launched Epysqli in the United States. This is the second eculizumab biosimilar to be commercialized. Epysqli will be available at a 30% discount to the list price (or wholesale acquisition cost) of the reference product Soliris.
Company Info
Biosimilars Review & Report
Biosimilars Review & Report (BR&R) provides education, commentary, and updates on the US biosimilar marketplace, including a free, updated database on all 351(k) biologic licensing applications to the FDA.
Founded: 2014